NCT04209296 is a clinical trial of Ketamine Hydrochloride in Major Depressive Disorder, sponsored by Brain and Cognition Discovery Foundation.

Who is sponsoring NCT04209296?

NCT04209296 is sponsored by Brain and Cognition Discovery Foundation.

What drugs are being tested in NCT04209296?

Interventions in NCT04209296: Ketamine Hydrochloride.

What condition does NCT04209296 study?

NCT04209296 studies Major Depressive Disorder, Bipolar Disorder, Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder.

Is NCT04209296 still recruiting?

NCT04209296 is currently completed. Last updated 12 August 2024.

Last reviewed 2024-08-12 · How we verify

NCT04209296

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chart Review of Patients Undergoing Ketamine Infusions

Completed Last updated 12 August 2024

What this trial tests

trial testing Ketamine Hydrochloride in Major Depressive Disorder in 891 participants. Completed in 14 September 2023.

Timeline

3 December 2019

Primary endpoint
14 September 2023

14 September 2023

Quick facts

Lead sponsor	Brain and Cognition Discovery Foundation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	891
Start date	3 December 2019
Primary completion	14 September 2023
Estimated completion	14 September 2023
Sites	1 location across Canada

Drugs / interventions tested

Ketamine Hydrochloride — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →
Bipolar Disorder — all drugs for Bipolar Disorder →
Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →
Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →

Sponsor

Brain and Cognition Discovery Foundation

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder or Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder.
Singewald N, Sartori SB, Reif A, Holmes A. · · 2023 · cited 40× · PMID 36623804 · DOI 10.1016/j.neuropharm.2023.109418
Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F, Rodrigues NB, Di Vincenzo JD, Chau EH, et al · · 2023 · cited 21× · PMID 36516343 · DOI 10.1111/bdi.13284
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
McIntyre RS, Rosenblat JD, Rodrigues NB, Lipsitz O, et al · · 2021 · cited 20× · PMID 34034067 · DOI 10.1016/j.psychres.2021.113993
Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Danayan K, Chisamore N, Rodrigues NB, Vincenzo JDD, et al · · 2023 · cited 17× · PMID 36889160 · DOI 10.1016/j.psychres.2023.115133
Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.
Fancy F, Rodrigues NB, Di Vincenzo JD, Chau EH, et al · · 2023 · cited 4× · PMID 38694999 · DOI 10.1176/appi.focus.23021022
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
Chisamore N, Danayan K, Rodrigues NB, Di Vincenzo JD, et al · · 2023 · cited 4× · PMID 37194253 · DOI 10.1177/02698811231171531
The Influence of Childhood Trauma on the Real‐World Effectiveness of Ketamine in Adults With Treatment‐Resistant Depression
Johnson D, Rodrigues N, Mansur R, McIntyre R, et al · · 2025

Verify or expand the search:

Other trials of Ketamine Hydrochloride

Trials testing the same drug.

NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT06090422 — Ketamine for Combined Depression and Alcohol Use Disorder · Phase 1, PHASE2 · not yet recruiting
NCT06496750 — Ketamine for Methamphetamine Use Disorder · Phase 2 · recruiting
NCT05973851 — The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Us · Phase 3 · recruiting
NCT06366334 — Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation · NA · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Brain and Cognition Discovery Foundation trials

Trials by the same sponsor.

NCT05029466 — Psilocybin for Treatment-Resistant Depression · Phase 2 · completed
NCT05047952 — Vortioxetine for Post-COVID-19 Condition · Phase 2 · completed
NCT04695405 — Pharmacogenetics Associated With IV Ketamine · completed
NCT03939676 — Evaluating Motivation and Reward Mechanisms and Brain Substrates in Adults With Obesity · completed
NCT03999567 — Validation Study: Mobile DSST on Cognition in Adults With MDD · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04209296 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brain and Cognition Discovery Foundation
Last refreshed: 12 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04209296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing